S-GROUP
10.5.2023 05:01:34 CEST | Business Wire | Press release
Researchers at the University of Jyväskylä have developed a method for corporations to calculate their biodiversity footprint. The pilot project focused on S Group’s biodiversity footprint. The outcome of the study will be a method freely available to all companies and organisations for the assessment of their impact on nature.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230509005817/en/
Researchers at the University of Jyväskylä have developed a method for corporations to calculate their biodiversity footprint. The pilot project focused on S Group’s biodiversity footprint. (Photo: Business Wire)
The interim report of the project published now indicates that food and fuels account for most of S Group’s biodiversity footprint, with the majority of the footprint falling on regions beyond Finland’s borders. Utility goods account for a significantly smaller portion—a few per cent—of the biodiversity footprint.
“Companies already routinely calculate their carbon footprints. This project demonstrates that they can also calculate their biodiversity footprint. A company like S Group, with operations in several different sectors, played a key role in the method’s development,” says Janne Kotiaho, Professor of Ecology at the University of Jyväskylä.
“You have to tackle climate and biodiversity challenges hand in hand. As opposed to climate efforts, biodiversity impacts are very local. The report shows that there is a need for increasingly strong cooperation between businesses and partners operating within the same geographic area. Companies must also start building new kinds of cooperation networks to reduce their negative impact on nature,” says Nina Elomaa, Senior Vice President, Sustainability, at S Group.
“You cannot manage something that you can’t measure. Stopping biodiversity loss requires a functional method for calculating biodiversity footprints. Any company that intends to make a serious effort to manage their biodiversity impact needs a method of this kind. We can take some national pride in Finland being at the forefront of this global development work,” says Lasse Miettinen, Director of Sustainability solutions at Sitra.
The theme is topical, given that nations around the world agreed on new international targets for halting biodiversity loss at the Montreal Biodiversity Conference in December. The global biodiversity framework agreed on also stated that, in the future, large and transnational companies should disclose their negative impact on biodiversity.
Biodiversity footprint maps impact on terrestrial and aquatic ecosystems
Through complex supply chains, a large part of the negative environmental impact attributable to Finnish consumption is generated across the globe, beyond Finland’s borders. According to the calculation model based on financial accounting and Finland’s international trade, more than 90 per cent of S Group’s global biodiversity footprint falls on regions outside Finland.
S Group aims to reduce its biodiversity impact through its climate work and by promoting more sustainable consumption and a planetary health diet. Concrete actions include policies related to raw materials and sourcing that aims to protect fish populations, for example, or ensure that no purchases are made from areas sensitive in terms of forest loss.
How S Group’s biodiversity footprint was assessed
The biodiversity footprint of S Group’s value chain and own operations was assessed with a method devised by the University of Jyväskylä School of Resource Wisdom – JYU.Wisdom.
The indicator of the biodiversity footprint is the share of the world’s species at risk of extinction, i.e. the Potentially Disappeared Fraction (PDF) of species. The indicator collects the PDF of various species under a single unit of measurement, similar to carbon footprint assessments, and enables the international comparison of different corporations’ biodiversity footprints.
The method’s further development continues.
For more information:
S Group - S Group (s-ryhma.fi)
JYU.Wisdom − School of Resource Wisdom — University of Jyväskylä
The Finnish Innovation Fund Sitra
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005817/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
